Compare OFS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFS | XLO |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.2M | 49.8M |
| IPO Year | N/A | 2021 |
| Metric | OFS | XLO |
|---|---|---|
| Price | $3.92 | $7.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 57.6K | 30.2K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | ★ 16.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $2.72 | $0.46 |
| 52 Week High | $9.31 | $9.25 |
| Indicator | OFS | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 51.40 |
| Support Level | $3.57 | $0.62 |
| Resistance Level | $4.08 | $9.22 |
| Average True Range (ATR) | 0.20 | 0.47 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 49.56 | 31.50 |
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.